PRECISION BIOSCIENCES INC

Precision BioSciences reported a Q2 2026 net loss of $32.7 million, with a cash balance of $112.4 million, expected to fund operations through 2028. The company announced significant clinical progress for PBGENE-HBV, demonstrating the first clinical biopsy evidence of direct cccDNA elimination and sustained pgRNA loss in 100% of evaluable patients. Additionally, PBGENE-DMD is actively recruiting patients for its Phase 1/2 trial, with initial safety data targeted for year-end 2026.

Precision BioSciences reported a net loss of $(32.65) million for Q2 2026, widening from $(23.52) million in Q2 2025. The company extended the maturity date of its $22.5 million term loan to December 31, 2029, enhancing financial flexibility. Cash and cash equivalents decreased to $86.08 million, while total liabilities increased significantly due to a rise in warrant liability. The company recognized $6.8 million in revenue from a TG Therapeutics clinical milestone and $4.0 million from an agriculture collaboration.

Precision BioSciences, Inc. announced significant changes to its senior leadership team, effective August 1, 2026. Alex Kelly was promoted from Chief Financial Officer to the newly created role of Chief Operating Officer. Naresh Tanna, previously VP of Investor Relations and Chief of Staff to the CEO, was appointed as the new Chief Financial Officer. Additionally, Mei Burris was designated as Principal Accounting Officer and Chief Accounting Officer, and other executive roles were clarified to support the advancement of the company's clinical programs.

Precision BioSciences, Inc. and Banc of California entered into a First Amendment to their Amended and Restated Loan and Security Agreement on June 10, 2026. This amendment extends the maturity date of the existing Term Loan from June 30, 2027, to December 31, 2029, providing the company with additional financial flexibility.

Precision BioSciences announced new and late-breaking clinical data from its Phase 1 ELIMINATE-B trial for PBGENE-HBV in chronic hepatitis B, presented at the EASL Congress 2026. The data showed PBGENE-HBV directly eliminated cccDNA, leading to a 1-log reduction in cccDNA-derived transcripts and permanent inactivation of viral replication. It also achieved pgRNA loss in 100% of patients with detectable pgRNA at baseline and demonstrated a manageable safety profile across multiple dosing cohorts. An investor webcast is scheduled to discuss these encouraging results.

Precision BioSciences, Inc. stockholders approved an amendment to the 2019 Incentive Award Plan, increasing the number of shares available for issuance by an additional 3,800,000. This approval occurred at the annual meeting on May 21, 2026. Stockholders also approved an amendment to the Certificate of Incorporation to exculpate certain officers as permitted by Delaware law, which became effective on May 22, 2026. Additionally, two Class I directors were elected, the appointment of Deloitte & Touche LLP as auditor was ratified, and executive compensation was approved on an advisory basis.

Precision BioSciences reported strong first-quarter 2026 financial results, with total revenues increasing to $10.8 million and net loss decreasing to $18.4 million. The company maintained a robust cash balance of $125.8 million, extending its cash runway through 2028. Significant progress was made across its clinical pipeline, including advancing the PBGENE-HBV and PBGENE-DMD programs, securing regulatory approvals, and receiving a $7.5 million milestone payment from TG Therapeutics.